Several existing drugs targeting IL17 could be tested for COVID-19 therapies (e.g. secukinumab [approved for arthritis, psoriasis, spondylitis], ABY-035 [for psoriasis; NCT02690142], BCD-085 [for arthritis; NCT03598751, for spondylitis; NCT03447704; for psoriasis; NCT03390101], bimekizumab [for arthritis; NCT04009499], CJM112 [for hidradenitis suppurativa; NCT02421172]). Here, IL17A is linked to arthritic joint disease.